A Study of Tarlatamab for People With Prostate Cancer

Part of paid clinical trials in San Diego, California.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07111507
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tarlatamab — DRUG
    Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.

Study Details

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

Key Dates

Start date
Jul 31, 2025
Status verified
Apr 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tarlatamab
    Participants will be treated with a lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.

Primary Outcome Measure

progression free survival (rPFS) [ Time Frame: up to 24 weeks ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)San DiegoCalifornia92103
Rana McKay, MD
858-657-7876
University of California San FranciscoSan FranciscoCalifornia94143
Rahul Aggarwal, MD
858-657-7876
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
Karen Autio, MD
646-422-4632
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew Jersey07748
Karen Autio, MD
646-422-4632
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
Karen Autio, MD
646-422-4632
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)CommackNew York11725
Karen Autio, MD
646-422-4632
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604
Karen Autio, MD
646-422-4632
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Karen Autio, MD
646-422-4632
Memorial Sloan Kettering Nassau (Limited Protocol Activities)UniondaleNew York11553
Karen Autio, MD
646-422-4632
Thomas Jefferson University HospitalPhiladelphiaPennsylvania19107
Kayvan Zarrabi, MD
215-955-8874

Find similar trials in San Diego, CA

By research site
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)· San Diego, CAUniversity of California San Francisco· San Francisco, CAMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)· Commack, NY

Related Studies